Skip to Main Content

WASHINGTON — Senate lawmakers are actively considering pegging the prices Medicare pays for drugs to those drug makers offer to other government programs like the nation’s veterans health program, according to sources familiar with the discussions as well as an internal slide deck obtained by STAT.

The proposal, known internally as domestic reference pricing, could have a multibillion-dollar impact on drug makers, which have long opposed allowing Medicare to negotiate over drug prices.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment